The online version of this article (doi:10.1186/s12943-017-0619-6) contains supplementary material, which is available to authorized users.
Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer.
Immunohistochemical staining for VASH2 was performed on 102 human pancreatic cancer samples. Pancreatic cancer cell line models exhibiting overexpression or knockdown of VASH2 were generated. Gene expression analyses were carried out to determine genes differentially regulated by VASH2. Putative transcription factors that are downstream mediators of gene expression regulated by VASH2 were queried bioinformatically. Dual-luciferase reporter assays and ChIP assays were performed to confirm transactivation of target genes following VASH2 overexpression or knockdown.
VASH2 protein expression was higher in human pancreatic cancer than in paired adjacent tissues and elevated VASH2 levels were associated with gemcitabine chemoresistance. In cell line models of pancreatic cancer, VASH2 expression induced gemcitabine chemoresistance in vitro and in vivo. It was discovered that expression of ribonucleotide reductase regulatory subunit M2 (RRM2) is regulated by VASH2; immunohistochemical analysis demonstrated a positive association of VASH2 expression and RRM2 expression in human pancreatic cancer tissues. Bioinformatics analyses revealed that induction of the Jun proto-oncogene (JUN) by VASH2 is responsible for upregulation of RRM2 expression; this JUN-dependent regulation of RRM2 by VASH2 was confirmed by chromatin immunoprecipitation and dual luciferase reporter assays, which demonstrated that JUN directly binds with the RRM2 promoter to activate transcription.
These data suggest that VASH2 reduces the chemosensitivity to gemcitabine in pancreatic cancer cells via JUN-dependent transactivation of RRM2.
Additional file 1: Sequences of primers and siRNAs. (DOC 26 kb)12943_2017_619_MOESM1_ESM.doc
Additional file 2: Representation of immunostaining pictures for weak and strong VASH2 staining in pancreatic cancer tissues. (TIF 3090 kb)12943_2017_619_MOESM2_ESM.tif
Additional file 3: Expression of VASH2 in stably transfected PANC-1 and SW1990 pancreatic cancer cells. PANC-1 cells were transfected with a vector expressing EGFP (PANC-1-EGFP) or VASH2 (PANC-1-VASH2), and SW1990 cells were transduced with a scrambled shRNA (SW1990-scramble) or a shRNA targeting VASH2 (SW1990-shVASH2). VASH2 protein expression was assessed by immunoblotting. (TIF 294 kb)12943_2017_619_MOESM3_ESM.tif
Additional file 4: Human gene expression analysis results using NimbleGen 12x135K microarrays. Differentially expressed genes were identified through Fold Change filtering. Fold change cutoffs of ≥ 3 (upregulation, 211 genes) or ≤ 0.33 (downregulation, 192 genes) were used to identify genes that were significantly differentially expressed. (XLS 69 kb)12943_2017_619_MOESM4_ESM.xls
Additional file 5: mRNA expression of JUN in PANC-1 pancreatic cancer cells transfected with different JUN-targeting siRNA. (TIF 454 kb)12943_2017_619_MOESM5_ESM.tif
Shibuya T, Watanabe K, Yamashita H, Shimizu K, Miyashita H, Abe M, Moriya T, Ohta H, Sonoda H, Shimosegawa T, et al. Isolation and characterization of Vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor Vasohibin. Arterioscler Thromb Vasc Biol. 2006;26:1051–7. CrossRefPubMed
Sun J, Tu M, Han B, Xue X, Zhang Y, Wei J, Chen J, Lu Z, An Y, Cai B, et al. Generation and characterization of rabbit polyclonal antibodies against Vasohibin-2 for determination of its intracellular localization. Int J Oncol. 2013;43:255–61. PubMed
Kim JC, Kim KT, Park JT, Kim HJ, Sato Y, Kim HS. Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome. Hepatogastroenterology. 2015;62:251–6. PubMed
Ge Q, Zhou J, Tu M, Xue X, Li Z, Lu Z, Wei J, Song G, Chen J, Guo F, et al. Nuclear vasohibin-2 promotes cell proliferation by inducing G0/G1 to S phase progression. Oncol Rep. 2015;34:1327–36. PubMed
Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:3928–35. CrossRefPubMed
Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009;15:2913–9. CrossRefPubMed
Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 20,20-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res. 2003;9:5000–8. PubMed
Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS, Swarts SG, Hess SM. Tumor uptake and elimination of 20,20-difluoro-20-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res. 2001;7:3263–8. PubMed
Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep. 2006;15:1299–304. PubMed
- Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II